A Cellectis Trial Death Points To Challenges Ahead For CAR-T
Excitement over the emerging cancer immunotherapy approach has been super-charged in recent weeks, but Cellectis said it will put two trials on hold after a patient death, a problem seen with similar products.
You may also be interested in...
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Clinical holds by the US FDA have risen 36% since 2014.
Incremental updates at the recent ASH meeting shed light on which products may follow Novartis' Kymriah and Gilead/Kite's Yescarta into the commercial market. Will it be Celgene and Bluebird or Celgene and Juno? Where do Pfizer, Servier and Cellectis stand with their off-the-shelf options?